
Genitourinary Cancers
Latest News

Latest Videos

CME Content
More News

Raoul S. Concepcion, MD, FACS, discusses how to sort through the massive amount of data in the urology space, gain a basic understanding of its significance, and determine its clinical utility.

Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses neoadjuvant immune checkpoint inhibition in patients with bladder cancer.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses emerging immunotherapeutic combinations in kidney cancer.

Kevin R. Loughlin, MD, MBA, discusses the diagnosis, staging, and management of penile cancer.

Arlene O. Siefker-Radtke, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with bladder cancer who have fibroblast growth factor receptor (FGFR)-altered tumors.

Shilpa Gupta, MD, discusses the tolerability and safety of pembrolizumab and bevacizumab in renal cell carcinoma, as well as the future of bladder cancer treatment in the neoadjuvant setting.

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the results of the CARMENA study in patients with metastatic renal cell carcinoma.

Providing comprehensive, compassionate, cost-effective care has been the guiding principle of Urology San Antonio. The practice manages over 200,000 visits and establishes relationships with more than 22,000 new patients each year.

















Toni K. Choueiri, MD, discusses some of the most significant data presented thus far in 2018 for the treatment of patients with renal cell carcinoma.





















































